Where AtriCure Stands With Analysts
Portfolio Pulse from Benzinga Insights
AtriCure (NASDAQ:ATRC) has received 5 analyst ratings in the last quarter, with 3 bullish and 2 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for AtriCure is $52.8, with a high of $60.00 and a low of $49.00, representing a 17.5% decrease from the previous target of $64.00. Analysts rate stocks based on future earnings potential and company risk profile, typically updating their ratings quarterly or after significant company events.
November 29, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AtriCure has a positive outlook from analysts with 3 bullish and 2 somewhat bullish ratings. The average price target is now $52.8, down from $64.00, indicating a potential downside according to analysts.
The reduction in the average price target for AtriCure suggests that analysts expect the stock to perform worse than previously anticipated. This could lead to a negative short-term impact on the stock price as investors adjust their expectations. However, the overall positive ratings may buffer some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100